HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


FACT: Facet Biotech Corp - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

FACET BIOTECH CORP (NASD)
FACT 15.77 N/A (N/A%) Vol.  0 N/A ET

Day Low - High N/A - N/A
52wk Low - High 5.86 - 18.35
Avg Volume 163,756
Industry MED-BIOMED/GENE
Market Cap 387.55 M
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -3.79
EPS Last Year -6.32
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


upgraded 02/06/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 02/05/2010
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
FACET BIOTECH CORP FACT PREMIUM
GILEAD SCIENCES GILD PREMIUM
ABRAXIS BIOSCI ABII PREMIUM
CURIS INC CRIS PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.00
ABR (Last Week) 1.00
# of Recs in ABR 3
Average Target Price 22.00
Industry Rank by ABR 68 out of 217
Rank in Industry 1 out of 162
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate FACT?
Buy
Sell
Find out what the Zacks Community
thinks of FACT at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR FACT
Zacks Equity Research: Report for FACT
Feb 05, 2010
Zacks Blog: Facet Rejects Biogen Again
Dec 11, 2009
Zacks Blog: Biogen Reports Higher Earnings
Oct 20, 2009
Zacks Blog: Zacks Analyst Blog Highlights: Biogen Idec Inc., Facet Biotech Corporation, Trubion Pharmaceuticals, Bristol-Myers Squibb and Acorda Therapeutics
Oct 20, 2009
Zacks Blog: Biogen Extends Hostile Bid
Oct 19, 2009
Zacks Blog: Zacks Analyst Blog Highlights: Facet Biotech Corporation, Biogen Idec Inc., Trubion Pharmaceuticals, Bristol-Myers Squibb and Acorda Therapeutics
Oct 12, 2009
Zacks Blog: Facet Investors Urged to Deny Offer
Oct 09, 2009
Zacks Blog: Biogen Launches Hostile Bid
Sep 23, 2009
More Zacks Commentary
NEWS
President Sergey Brin Sells $44.3M Worth of Google - TheStreet.com
Feb 05, 2010
Facet Biotech to Present at 12th Annual Bio CEO & Investor Conference
Feb 02, 2010
President James Truchard Sells $7.7M National Instruments - TheStreet.com
Feb 01, 2010
Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors
Jan 11, 2010
Facet Biotech Announces Enrollment of First Patient in Phase 2 Studyof Elotuzumab in Patients With Relapsed Multiple Myeloma
Jan 11, 2010
BiomedReports: News and FDA Updates for Facet Biotech (NASDAQ:FACT), Biogen (NASDAQ:BIIB), Glowpoint (OTC:GLOW), Hop-on (OTC:HPNN)
Dec 18, 2009
PennyStockChaser.com: Pennystockchaser.com: www.pennnystockchaser.com: Penny Stock Chaser Alerts, December 17, 2009: CBEY, WPRT, FACT and HSNI
Dec 17, 2009
Facet Biotech rejects Unsolicited Tender Offer from Biogen Idec (FACT,BIIB)
Dec 17, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate -1.38 -0.91 -6.01 -3.79
Number of Estimates 2 1 2 2
Low Estimates -1.59 -0.91 -6.22 -5.05
High Estimate -1.16 -0.91 -5.79 -2.52
Year Ago EPS -1.63 -1.22 -5.94 -6.01
EPS Growth 15.64% 25.41% -1.09% 36.97%

More Estimates

COMPANY DESCRIPTION
Facet Biotech Corporation offers biotechnology research services for drug and pharmaceutical products development. It is dedicated to advancing its pipeline of four clinical-stage products and leveraging its research and development capabilities to identify and develop new drugs. The ultimate goal of the company is of developing therapeutics that will improve people's lives. The company is based in Redwood City, California.

Full Company Report
FINANCIALS
EPS TTM -6.32
Sales 18.26
Net Income -160.92
Price/Earnings N/A
Price/Book 1.13
Price/Cash Flow N/A
Price/Sales 10.29


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research